Summary:
- Viking Therapeutics, Inc. (VKTX, Financial) will announce its Q1 2025 financial results on April 23, 2025.
- Analysts project an average price target of $97.40, suggesting significant upside potential.
- The stock receives an "Outperform" consensus rating from brokerage firms.
Viking Therapeutics, Inc. (VKTX) has captured investor attention as it gears up to announce its first-quarter 2025 financial results. Scheduled for release post-market on April 23, 2025, the biopharmaceutical company will follow up with a conference call at 4:30 p.m. Eastern Time to delve into these results and share corporate strategies.
Wall Street Analysts Forecast
Analysts are closely watching Viking Therapeutics Inc (VKTX, Financial), offering a one-year average price target of $97.40. This figure represents a potential upside of 312.71% from its current trading price of $23.60. High and low estimates range between $164.00 and $30.00, respectively, reflecting varied expectations. For a comprehensive look at these projections, visit the Viking Therapeutics Inc (VKTX) Forecast page.
Moreover, the consensus recommendation among 18 brokerage firms stands at an average of 1.7. This "Outperform" rating indicates positive sentiment, using a scale where 1 equates to a Strong Buy and 5 to a Sell.
